Objective. The purpose of this study is to examine the difference between the numbers of patients in rheumatoid arthritis (RA) who are eligible to TNF inhibitors by the past Korean National Health Insurance reimbursement guideline and by the disease activity score with 28-joint assessment (DAS28) based criteria. Methods. Data were obtained from a multi-center registry for biologics users in Korean RA patients, BIOlogics Pharmacoepidemiologic StudY (BIOPSY). DAS28 was calculated based on either ESR or CRP, and DAS28 of more than 5.1 or between 3.2 and 5.1 with radiographic changes was defined as a cut-off point for the initiation of TNF inhibitors. For the maintenance criteria, we used both of improving in DAS28 score (＞1.2) and low disease activity (DAS 28＜3.2). Differences between the numbers in each step by two criteria were described with Chi-square test and Kappa agreement. Results. Of the 489 patients in BIOPSY, 299 were included in this study. Among them, 278 patients (93.0%) were eligible of TNF inhibitors when we applied the new initiation criteria with DAS28-ESR, and 244 patients (81.6%) were indicated for TNF inhibitors with DAS28-CRP. For the maintenance criteria, a low disease activity (DAS28＜3.2) in 3 months after starting TNF inhibitors is too strict for achieving (33.6% with DAS28-ESR and 50.0% with DAS28-CRP). Instead, decreasing DAS28 by more than 1.2 is more reasonable as a tool for deciding early responsiveness of TNF inhibitors in RA patients (81.2% both with DAS28-ESR and DAS28-CRP). Conclusion. Our results show that the candidates for TNF inhibitors will be enormously changed according to a change in the reimbursement criteria. To define appropriate patients to receive TNF inhibitors, a further study with regard to the impact of changes in the reimbursement criteria on the outcomes of RA patients will be required. Number (%). 1 patient had missing value with DAS28-ESR after 3 months. RA: rheumatoid arthritis, TNF: tumor necrosis factor, DAS28: disease activity score with 28-joint assessment, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein. Number (%), mean±SD. RA: rheumatoid arthritis, DAS28: disease activity score with 28-joint assessment, CRP: C-reactive protein, SD: standard deviation, ESR: erythrocyte sedimentation rate, DMARD: disease modifying antirheumatic drug.
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DAS28-CRP는 DAS28-ESR을 대체하기 위해 개발된 질병활 성도 평가도구로서 질병활성도의 중증도를 평가할 때
DAS28-ESR과 같은 기준을 적용하고 있다. 하지만, DAS28-CRP는 DAS28-ESR에 비해 질병활성도가 과소평가된다고 알
